Article summary
Texas Ibogaine Research Corporation, Psyence BioMed’s wholly owned subsidiary, will work with Benuvia Operations at its Round Rock, Texas facility to manufacture ibogaine API under cGMP standards. The partnership builds on a proposed exclusive US supply and distribution agreement with PsyLabs, with a definitive agreement expected by 30 November 2026. Ibogaine is not FDA-approved, and production remains subject to DEA quotas, import requirements and other regulatory authorisations.
Continue to the original publication for the complete article.